Skip to main content
×
×
Home

Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have

  • Fredrik Hieronymus (a1), Alexander Lisinski (a1), Jakob Näslund (a1) and Elias Eriksson (a1)
Abstract

Funded by the Danish state to provide guidance in health-related matters, the Copenhagen Trial Unit (CTU) at Rigshospitalet may cause considerable societal harm if allowing their analyses to be influenced by bias and prejudice rather than rigor and impartiality. This is why we found it worthwhile to comment on a report from the CTU in which the authors invoked analyses marred by numerous errors and methodological mistakes to claim that selective serotonin reuptake inhibitors (SSRIs) are harmful and ineffective. The CTU group has now produced a response to our comment which is on par with their original contribution in terms of bias, misconceptions and mistakes. Our conclusion is that the reputation of the CTU would be best served by the authors asking for retraction of their SSRI paper.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
*Elias Eriksson, Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, POB 431, SE 405 30 Gothenburg, Sweden. Tel: +46709555055; Fax: +4631821795; E-mail: elias.eriksson@neuro.gu.se
References
Hide All
1. Jakobsen, JC, Katakam, KK, Schou, A, Hellmuth, SG, Stallknecht, SE, Leth-Møller, K, Iversen, M, Banke, MB, Petersen, IJ, Klingenberg, SL, Krogh, J, Ebert, SE, Timm, A, Lindschou, J, Gluud, C. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 2017;17:58.
2. Hieronymus, F, Lisinski, A, Naslund, J, Eriksson, E. Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective. Acta Neuropsychiatr 2017;17. https://doi.org/10.1017/neu.2017.23 [Epub ahead of print].
3. Katakam, KK, Sethi, NJ, Jakobsen, JC, Gluud, C. Great boast, small roast on effects of selective serotonin reuptake inhibitors: response to a critique of our systematic review. Acta Neuropsychiatr 2018; 115 [Epub ahead of print].
4. TV 2 (Denmark). Nyt studie: 250.000 danskere tager pillerne – men de har ingen effekt og mange alvorlige bivirkninger, 2017. Available at http://nyheder.tv2.dk/samfund/2017-02-09-nyt-studie-250000-danskere-tager-pillerne-men-de-har-ingen-effekt-og-mange. Accessed April 5, 2018.
5. Jakobsen, JC, Naqash, JS, Gluud, C. Videnskab.dk – Forskere: Lægemiddelstyrelsens kritik af ‘lykkepille’-studie holder ikke, 2017. Available at https://videnskab.dk/krop-sundhed/forskere-laegemiddelstyrelsens-kritik-af-lykkepille-studie-holder-ikke. Accessed April 5, 2018.
6. Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, Leucht, S, Ruhe, HG, Turner, EH, Higgins, JPT, Egger, M, Takeshima, N, Hayasaka, Y, Imai, H, Shinohara, K, Tajika, A, Ioannidis, JPA, Geddes, JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391:13571366.
7. Adamson, SJ, Sellman, JD, Foulds, JA, Frampton, CM, Deering, D, Dunn, A, Berks, J, Nixon, L, Cape, G. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2015;35:143149.
8. Pettinati, HM, Oslin, DW, Kampman, KM, Dundon, WD, Xie, H, Gallis, TL, Dackis, CA, O’Brien, CP. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010;167:668675.
9. Detke, MJ, Wiltse, CG, Mallinckrodt, CH, McNamara, RK, Demitrack, MA, Bitter, I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharm 2004;14:457470.
10. Lundbeck. Clinical Trial Report Summary – Study 99024, 2005. Available at http://www.lundbeck.com/upload/trials/files/pdf/completed/99024_CTRS_final_30Dec2005.pdf. Accessed April 5, 2018.
11. GlaxoSmithKline. Scientific Result Summary – 29060.487, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2063.pdf. Accessed April 5, 2018.
12. Feighner, JP, Overo, K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999;60:824830.
13. Claghorn, JL, Earl, CQ, Walczak, DD, Stoner, KA, Wong, LF, Kanter, D, Houser, VP. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113120.
14. Wernicke, JF, Dunlop, SR, Dornseif, BE, Bosomworth, JC, Humbert, M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183188.
15. Leucht, S Reviewer report on the original manuscript, 2016. Available at https://static-content.springer.com/openpeerreview/art%3A10.1186%2Fs12888-016-1173-2/12888_2016_1173_ReviewerReport_V0_R1.pdf. Accessed April 5, 2018.
17. Ball, WA, Snavely, DB, Hargreaves, RJ, Szegedi, A, Lines, C, Reines, SA. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Hum Psychopharmacol 2014;29:568577.
18. U.S. Food and Drug Administration CfDEaR. Statistical review – Lexapro NDA 021323, 2001. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Statr.pdf. Accessed April 5, 2018.
19. GlaxoSmithKline. Scientific Result Summary – 29060.810, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2204.pdf. Accessed April 5, 2018.
20. GlaxoSmithKline. Scientific Result Summary – 29060.785, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2202.pdf. Accessed April 5, 2018.
21. GlaxoSmithKline. Scientific Result Summary – 29060.115, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2060.pdf. Accessed April 5, 2018.
22. EliLilly. Clinical Study Summary: Study F1J-MC-HMAQa, 2004. Available at https://assets.contentful.com/hadumfdtzsru/3FeEMX77nykUwsguguMgae/4f385628fa4e88bf5ec62fca7aedc23d/Duloxetine-F1J-MC-HMAQ-_Study-Group-A_.pdf. Accessed April 5, 2018.
23. EliLilly. Clinical Study Summary: Study F1J-MC-HMATb, 2004. Available at https://assets.contentful.com/hadumfdtzsru/5CF1Of1xBu0iwq8MWwEGOY/00f0112ecaebe9e28c5ace5c2c6087f4/Duloxetine-F1J-MC-HMAT-_Study-Group-B_.pdf. Accessed April 5, 2018.
24. EliLilly. Clinical Study Summary: Study F1J-MC-HMAQb, 2004. Available at https://assets.contentful.com/hadumfdtzsru/5FZ15aVRBKKsmKIoeSgsMO/b1b988aefbb263aabdb413af7f3534a7/Duloxetine-F1J-MC-HMAQ-_Study-Group-B_.pdf. Accessed April 5, 2018.
25. EliLilly. Clinical Study Summary: Study F1J-MC-HMATa, 2004. Available at https://assets.contentful.com/hadumfdtzsru/1D76MTikKkeSIuOS4SgQcq/433330f08ad190a430f5d0f2140cb4b3/Duloxetine-F1J-MC-HMAT-_Study-Group-A_.pdf. Accessed April 5, 2018.
26. GlaxoSmithKline. Scientific Result Summary – 29060.251, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/1989.pdf. Accessed April 5, 2018.
27. GlaxoSmithKline. Scientific Result Summary – PAR 29060.442, 2005. Available at https://gsk-clinicalstudyregister.com/files2/2323.pdf. Accessed April 5, 2018.
28. Keller, M, Montgomery, S, Ball, W, Morrison, M, Snavely, D, Liu, G, Hargreaves, R, Hietala, J, Lines, C, Beebe, K, Reines, S. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216223.
29. Liu, KS, Snavely, DB, Ball, WA, Lines, CR, Reines, SA, Potter, WZ. Is bigger better for depression trials? J Psychiatr Res 2008;42:622630.
30. Pharmacia&Upjohn. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder: a phase III, randomized, double-blind, placebo- and active-treatment-controlled, parallel-group, 8-week study of reboxetine, given orally twice daily to adult patients with major depressive disorder; final report of the study protocol M/2020/0046, 2001. Available at http://www.iqwig.de/download/Studie_046.pdf. Accessed April 5, 2018.
31. Pharmacia&Upjohn. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder: a phase III, randomized, double-blind, placebo- and active-treatment-controlled, parallel-group, 8-week study of reboxetine, given orally twice daily to adult patients with major depressive disorder: final report of the study protocol M/2020/0047, 2001. Available at http://www.iqwig.de/download/Studie_047.pdf. Accessed April 5, 2018.
32. Pharmacia&Upjohn. Reboxetine (PNU-155950E) versus placebo and fluoxetine in a controlled, randomized, double-blind, multicenter study of treatment in major depressive disorders: final report of the study protocol 97-CRBX-050, 2001. Available at http://www.iqwig.de/download/Studie_050.pdf. Accessed April 5, 2018.
33. Eyding, D, Lelgemann, M, Grouven, U, Härter, M, Kromp, M, Kaiser, T, Kerekes, MF, Gerken, M, Wieseler, B. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737.
34. Massana, J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59:810.
35. Pfizer. PhRMA Web Synopsis for Protocol A0501075 (NCT00636246), 2008. Available at http://www.rxarchives.org/uploads/2/4/4/6/24466638/a0501075_online.pdf. Accessed April 5, 2018.
36. Gastpar, M, Singer, A, Zeller, K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006;39:6675.
37. EliLilly. ClinicalTrials.gov – Study Results for NCT01808612, 2014. Available at https://clinicaltrials.gov/ct2/show/results/NCT01808612. Accessed April 5, 2018.
38. Pfizer. PhRMA Web Synopsis for Protocol A9001337 (NCT00406952), 2008. Available at http://www.rxarchives.org/uploads/2/4/4/6/24466638/a9001337_online.pdf. Accessed April 5, 2018.
39. Novartis. Clinical Trial Report for CAGO178A2303, 2009. Available at http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2659. Accessed April 5, 2018.
40. Servier. EudraCT Clinical Trial Results – CL3-01574-237, 2016. Available at https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005612-26/results. Accessed April 5, 2018.
41. Sweeting, MJ, Sutton, AJ, Lambert, PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:13511375.
42. Kranzler, HR, Mueller, T, Cornelius, J, Pettinati, HM, Moak, D, Martin, PR, Anthenelli, R, Brower, KJ, O’Malley, S, Mason, BJ, Hasin, D, Keller, M. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006;26:1320.
43. Byerley, WF, Reimherr, FW, Wood, DR, Grosser, BI. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988;8:112115.
44. Cohn, JB, Wilcox, C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46(Pt 2):2631.
45. Itil, TM, Shrivastava, RK, Mukherjee, S, Coleman, BS, Michael, ST A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 1983;15(Suppl 3):433S438SS.
46. Olie, J, Gunn, K, Katz, E. A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression. Eur Psychiatry 1997;12:3441.
47. Sramek, JJ, Kashkin, K, Jasinsky, O, Kardatzke, D, Kennedy, S, Cutler, NR. Placebo-controlled study of ABT-200 versus fluoxetine in the treatment of major depressive disorder. Depression 1995;3:199203.
48. Ravindran, AV, Teehan, MD, Bakish, D, Yatham, L, O’Reilly, R, Fernando, ML, Manchanda, R, Charbonneau, Y, Buttars, J. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum Psychopharmacol 1995;10:273281.
49. GlaxoSmithKline. Scientific Result Summary – 29060.279, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2866.pdf. Accessed April 5, 2018.
50. Mancino, MJ, McGaugh, J, Chopra, MP, Guise, JB, Cargile, C, Williams, DK, Thostenson, J, Kosten, TR, Sanders, N, Oliveto, A. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol 2014;34:234239.
51. ClinicalTrials.gov. Study results for NCT00654953, 2011. Available at https://clinicaltrials.gov/ct2/show/results/NCT00654953?sect=X30156. Accessed April 5, 2018.
52. Timmerby, N, Andersen, JH, Sondergaard, S, Ostergaard, SD, Bech, P. A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6). Psychother Psychosom 2017;86:141149.
53. Jakobsen, JC, Simonsen, E, Rasmussen, KB, Gluud, C. Is the total score of the Hamilton Depression Rating Scale associated with suicide attempts or suicides? Br J Med Med Res 2013;3:140152.
54. Hieronymus, F, Emilsson, JF, Nilsson, S, Eriksson, E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2016;21:523530.
55. Jakobsen, JC, Nielsen, EE, Feinberg, J, Katakam, KK, Fobian, K, Hauser, G, Poropat, G, Djurisic, S, Weiss, KH, Bjelakovic, M, Bjelakovic, G, Klingenberg, SL, Liu, JP, Nikolova, D, Koretz, RL, Gluud, C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Acta Neuropsychiatrica
  • ISSN: 0924-2708
  • EISSN: 1601-5215
  • URL: /core/journals/acta-neuropsychiatrica
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
WORD
Supplementary materials

Hieronymus et al. supplementary material
Hieronymus et al. supplementary material 1

 Word (28 KB)
28 KB
UNKNOWN
Supplementary materials

Hieronymus et al. supplementary material
Hieronymus et al. supplementary material 2

 Unknown (21 KB)
21 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed